Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: A phase II study

Cancer Chemotherapy and Pharmacology

Volumn 57, Issue 6, 2006, Pages 796-800

  Stathopoulos, G P ^a   Christodoulou, Ch ^a   Stathopoulos, J ^a   Skarlos, D ^a   Rigatos, S K ^b   Giannakakis, Th ^b   Armenaki, O ^c   Antoniou, D ^c   Athanasiadis, A ^d   Giamboudakis, P ^c   Dimitroulis, J ^c   Georgatou, N ^c   Katis, K ^c  

^a Errikos Dunant Hospital   (Greece)

^b Agioi Anargyri Hospital   (Greece)

^c SOTIRIA GENERAL HOSPITAL   (Greece)

^d Oncology Department   (Greece)

Author keywords

Paclitaxel; SCLC; Topotecan; Weekly administration

Indexed keywords

CYTOTOXIC AGENT; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; TOPOTECAN;

EID: 33645732072     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0085-5     Document Type: Article

References (28)

1. Burris HA III, Hanauske AR, Jahnson RK et al. (1992) Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 84:1816-1821
2. Ardizzoni A, Hansen H, Dombernowsky P, et al. (1997) Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. J Clin Oncol 15:2090-2096
3. Markman M (1997) Topotecan: an important new drug in the management of ovarian cancer. Semin Oncol 4 (suppl 5):55-58
4. Bokkel Huinick WT, Gore M, Carmichael J. et al. (1997) Topotecan vs paclitaxel for the treatment or recurrent epithelial ovarian cancer. J Clin Oncol 15:2183-2187
5. Giaccone G (1989) Second line chemotherapy in small-cell lung cancer. Lung Cancer 5:207-213
6. Stathopoulos GP, Rigatos SK, Christodoulou Ch. et al. (2004) Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study. Cancer Chemother Pharmacol 54:259-264
7. Nabholtz JM, Gelmon K, Bontenbal M, et al. (1996) Multicenter randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867
8. Miller AB, Hoogstraten B, Staqnet M (1981) Reporting results of cancer treatment. 47:207-214
9. Murren J, Glatstein E, Pass PI (2001) Small cell lung cancer. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer of the lung. Cancer principles and practice of oncology, 6th edn. Lippincott Williams and Wilkins, Philadelphia, pp 983-1018
10. Clark PI, Slevin ML, Joel SP, et al. (1994) A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12:1427-1432
11. Smith IE, Harland SJ, Robinson BA et al. (1985) Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. Cancer Treat Rep 69:43-47
12. Evans WK, Feld R, Osoba D, et al. (1984) VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer. Cancer 53:1461-1465
13. Evans WK, Shepherd FA, Feld R, et al. (1985) VP-16 and cisplatin as a first-line therapy for small-cell lung cancer. J Clin Oncol 3:1471-1475
14. Roth BJ, Johnson DH, Einhorn LH et al. (1992) Randomized study of cyclophosphamide, doxorubicin and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10:282-291
15. Ettinger DS, Finkelstein DM, Abeloff MD, et al. (1990) A randomized comparison of standard chemotherapy versus alternating chemotherapy and maintenance versus no maintenance therapy for extensive-stage small-cell lung cancer: a phase III study of the Eastern Cooperative Oncology Group. J Clin Oncol 8:230-235
16. Arriagada R, Le Chevallier T, Pignon JP et al (1993) Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 329:1848-1853
17. Pujol JL, Donillard JY, Riviere A, et al. (1997) Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study. J Clin Oncol 15:2082-2089
18. Thatcher N, Girling DJ, Hopwood P, et al. (2000) Improving survival without reducing quality of life in small- cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 18:395-404
19. Hryniuk W, Bush H. (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2: 281-285
20. Souhami RL, Rudd R, Ruiz de Elvira MC, et al. (1994) Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 12:1806-1813
21. Murray N, Shah A, Osoba D, et al. (1991) Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer. J Clin Oncol 9:1632-1637
22. Murray N, Livingston R, Shepherd F, et al. (1997) Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an intergroup study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 17: 2300-2308
23. Frasci G, Nicollela G, Comella P, et al. (2001) A weekly regimen of cisplatin, paclitaxel and Topotecan with granulocyte-colony stimulating factor support for patients with extensive disease small cell lung cancer: a phase II study. Br J Cancer 84:1166-1171
24. Klaassen V, Wilke H, Strumberg D, et al. (1996). Phase I study with a weekly 1-h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 32A:547-552
25. Seidman AD, Hudis CA, Albanel J. et al. (1998). Dose-dense therapy with weekly 1-h paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:353-361
26. Chank RS, Fracasso PM, Picus J. (1999). A phase I study of weekly topotecan as a bolus infusion [abstract]. Proc Am Soc Clin Oncol 18:207a
27. Rowinsky EK. (2002) Weekly topotecan: an alternative to topotecan's standard dailyx5 schedule? Oncologist 7:324-329
28. Schiller JH, Adak S, Cella D, et al. (2001) Topotecan vs observation after cisplatin plus etoposide in extensive stage SCLC: E7593 - a phase III trial of the Eastern Cooperative Group. J Clin Oncol 19:2114-2122